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64 Poster Session-Iupregulation of CDKN2A and XAF1 expressions correlate with
downregulation of their downstream target proteins including phos-
phorylated Rb and XIAP, respectively. Based on the present data and
our previously published results, the synergistic effects of DAC and
Bu involve cell cycle arrest and apoptosis induction. Our results sug-
gest that DNA methylation status may be used to identify leukemia
patients who could benefit from Bu-DAC combinations to achieve
improved leukemic cytoreduction with the conditioning program
prior to stem cell transplantation.171
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) AFTER FIRST RE-
LAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOCYTIC LEUKEMIA
(ALL)
Arnold, R.1, Terwey, T.1, Hemmati, P.1, le Coutre, P.1, Neuburger, S.1,
Dorken, B.1, Massenkeil, G.2, Gokbuget, N.3 1 Charite University Medi-
cine, Berlin, Germany; 2 Klinikum Gu¨tersloh, Guetersloh, NRW,
Germany; 3 Frankfurt University, Frankfurt, Hessen, Germany
70 adult ALL patients (pts) were transplanted after 1. relapse
(leukemic blasts .5% in bone marrow or central nervous system
involvement) in a single center between 1995 and 2007. 2 pts
were excluded from the analysis because diagnosis of ALL was
made in childhood and they were transplanted in adult age. Median
age of the analyzed 68 pts was 28 years (16–54). 43 pts were male,
25 female. 32 pts were transplanted in 1. relapse, 24 pts in CR2 and
12 pts beyond CR2 (.CR2). Stem cell donors were HLA identical
sibling (n 5 24), identical twin (n 5 1), HLA identical child (n 5 1)
and unrelated donors (n 5 42). Standard conditioning was
12GyTBI and cyclophosphamide (CY) or VP16 (myeloablative
conditioning 5 MAC). Pts with comorbidities and contraindica-
tions against MAC received a dose reduced regimen (RIC) with
FLUD, BU and ATG (n 5 3). 18/68 pts (26%) are alive in
CCR, 50/68 pts (74%) are dead. Causes of death were leukemia
in 30/50 and transplant related morbidity, TRM in 20/50 pts
(GvHD and/or infection). For the whole patient group, probability
of survival (prob OS) at 7 years is 0.21 as is disease free survival.
Prob TRM is 0.43. Prob OS regarding stage of disease at SCT
was 0.26 for pts transplanted in 1. relapse, 0.23 for pts transplanted
in CR2 and 0.08 for pts transplanted beyond CR2. Prob OS after
unrelated donor or family donor transplantation was not different
(0.20 vs 0.22). Influence of leukemic risk factors on the prob OS
was analyzed. Risk group at diagnosis and during chemotherapy
(standard vs high risk group, criteria according to the GMALL
Studies) had no significant influence on the prob OS: 0.18 vs
0.25. Pts with B-lineage ALL had a prob OS of 0.25 vs 0.08 in
pts with T-lineage (n. s.). The median duration of 1. remission
for all pts was 9 months (1–72). Prob OS for pts with a remission
duration #9 months or .9 months was 0.24 and 0.17, resp. In con-
clusion, allogeneic SCT can cure ALL pts after 1. clinical relapse.
Our data show a high relapse rate even after standard conditioning
with 12GyTBI. Since conditioning can not be intensified further
because of high TRM, another transplant strategy should be dis-
cussed. Analysis of minimal residual disease (MRD) should be
done regularly during therapy and follow up of ALL pts. If molec-
ular relapse is detected, allogeneic SCT should be performed im-
mediately to avoid therapy refractory clinical relapse. In this
setting 5 pts with MRD positivity were transplanted in CR1 and
4/5 pts are alive in CCR.172
SAFETY AND EFFICACY OF FLUDARABINE AND PK-TARGETED INTRAVE-
NOUS BUSULFAN BEFORE ALLOGRAFTING FOR ADULT ALL
Anasetti, C., Santarone, S., Alsina, M., Ayala, E., Field, T., Kharfan-
Dabaja, M., Ochoa, L., Perez, L., Perkins, J., Raychaudhuri, J.,
Sullivan, D., Fernandez, H. Moffitt Cancer Center, Tampa, FL
Remission consolidation with allogeneic blood or marrow trans-
plantation improves survival of young patients with acute lymphoid
leukemia (ALL), but the potential benefit of transplantation in older
patients is offset by regimen toxicity and non-relapse mortality. Bu-
sulfan is not thought to be an effective drug for ALL, presumably be-
cause of intrinsic resistance of ALL to alkylating agents, or perhapsbecause of the large variability in busulfan pharmacokinetics and er-
ratic drug exposure. Here we report results of treatment with a PK-
targeted intravenous busulfan regimen in 25 adults with ALL. Pa-
tient age was 23–55 (median 40) years, 13 were treated in first com-
plete remission, 10 in second remission, and 2 with resistant disease.
Treatment was with 4 consecutive daily doses of fludarabine 40 mg/
m2, followed by intravenous busulfan, administered on days 1 and 2
at 130–145 mg/m2 daily over 4 hours with PK-sampling and mass
spectrometry assay. On days 3 and 4 busulfan dose was adjusted to
target an average area under the concentration curve of 5300 6
530 mMol*min/L for each of the four days. Donors were siblings
(14), or unrelated (11). Grafts were T-replete, filgrastim-mobilized
hematopoietic blood cells. GVHD prophylaxis was tacrolimus plus
methotrexate or mycophenolate mofetil. Mortality from all non-
relapse causes was 4% at 100 days, and 8% at one year. The one-
year overall survival (OS) was 66%, and relapse-free survival (RFS)
was 62%, with a median follow-up of 1.3 years for live patients.
For patients transplanted in CR1, one-year OS was 77% and RFS
70%; in CR2, OS and RFS were 58%; and with resistant disease,
OS and RFS were 0%. OS was 56% in patients up to 40 years, and
67% in patients 41–55 years old, with disease status and stage simi-
larly distributed in younger and older cohorts. With this treatment
protocol, the one-year non-relapse mortality is identical to what is
observed with non-transplant therapies. When compared to irradia-
tion-containing regimens, fludarabine and PK-targeted busulfan ap-
pear much safer and similarly effective in controlling ALL, providing
a treatment option for all adult patients with ALL. A multicenter
study comparing this transplant protocol against post-remission che-
motherapy for adult ALL is warranted.173
CLOFARABINE-INDUCED REMISSION IN RELAPSED PEDIATRIC ACUTE
MYELOGENOUS LEUKEMIA
Gordon, C., Megason, G., Ledbetter, A. University of Mississippi Medical
Center, Jackson, AZ
Despite improvements, the prognosis for children with recurrent
or progressive acute myeloid leukemia (AML) remains poor; the 5-
year relative survival rate for children under age 15 yrs is 54% (Jemal,
et al.,Ca Cancer J Clin 2008). Early relapse, defined as relapse within
18 months or less from time of initial diagnosis, is associated with
a second CR rate of about 50% and an overall survival of\10%
(Stahnke, K. et al. Leuk 1998). The second generation purine nucle-
oside analog clofarabine was designed to improve on the efficacy and
safety of cladribine and fludarabine. Interest in the utility of clofara-
bine in the treatment of pediatric patients with AML was stimulated
by its Food and Drug Administration approval for the treatment of
pediatric patients with relapsed ALL previously treated with at least
2 regimens. We report on our experience using clofarabine in 6 pe-
diatric patients with relapsed AML, 4 of whom achieved complete re-
mission (CR) with this single agent. All patients received clofarabine
IV at the recommended dose of 52 mg/m2/day for 5 days, with cycles
every 2 to 6 wks depending on count recovery. Patient 1, who never
achieved CR with prior therapies, received clofarabine after she re-
lapsed 6 mos.following a bone marrow transplant (BMT); she
achievedCR after 2 treatment cycles. Despite CR, this severely ill pa-
tient ultimately died with multiple organ failure, pneumonia, and
sepsis. Patient 2 obtained a CR after one cycle of clofarabine and
CR continues after 7 cycles. However, the original plan to maintain
this patient on clofarabine for 1 yr. was not achieved because of
chronic transfusion dependent thrombocytopenia. Patient 3 achieved
a CR after one cycle of clofarabine and received an additional cycle as
maintenance while awaiting BMT. Patient 4 had a CR with one cycle
of clofarabine following a relapse after a first BMT. The patient re-
ceived 2 additional cycles as maintenance before proceeding to a 2nd
BMT. This patient relapsed after the second BMT and is currently
receiving induction with clofarabine. Patients 5 & 6 had not re-
sponded well to previous treatments and failed to respond to a single
cycle of clofarabine. Patient 5 never achieved CR despite gemtuzu-
mab and BMT. Patient 6 had an unsustained CR2 with gemtuzumab
and failed subsequent therapies. Our experience indicates that sin-
gle-agent clofarabine as induction therapy can provide durable
CRs in pediatric patients with relapsed AML and provide a bridge
to subsequent BMT.
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Age at Prior Response CurrentPt # diagnosis Marrow Treatment to CLO Status1 11 11q23 1-Ara-C/
Dauno/
6-TG (induction
failure)CR (2) Died with
fungal sepsis2 8 11q23 1-Ara-C/
Dauno/VP/
L-ASP (CR-1)CR (1) CR continues
after 7 cycles
of CLO but
has chronic
thrombocytopenia3 13 t(8;21) 1-Ara-C/
Dauno/etoposide/
IT1Ara-C/
Mito (CR-1)CR (1) In CR,
undergoing BMT4 4 Monosomy 7 1-Ara-C/VP/
Dauno/
etoposide
(CR-1)CR (1) Relapsed after
2nd BMT,
undergoing
induction
with CLO5 10 Monosomy
5, 181-Ara-C/
etoposide/
6-TG/Dauno/
gemtuzumab/
Mito/IT 1
Ara-C (PR)No response
(1)Died of
progressive disease
and toxicities
following
BMT6 1.5 Noninformative 1-Ara-C/
Dauno/
etoposide/
6-TG/Mito/No response
(1)Died of
progressive
diseaseCLO: clofarabine; Ara-C: cytarabine; Dauno: daunorubicin; 6-TG: 6-thi-
oguanine; CR: complete remission; VP: etoposide1 cisplatin; L-ASP: L-
asparaginase; IT: ifosfamide1 paclitaxel; Mito: mitoxantrone; PR: partial
response.LYMPHOMA/MULTIPLE MYELOMA
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FUSION CELL VACCINATION IN CONJUNCTION WITH STEM CELL TRANS-
PLANTATION IS WELL TOLERATED, INDUCES ANTI-TUMOR IMMUNITY
AND IS ASSOCIATED WITH RESPONSES IN PATIENTS WITH MULTIPLE
MYELOMA
Avigan, D.1, Rosenblatt, J.1, Vasir, B.2, Wu, Z.2, Bissonnette, A.2,
Somaiya, P.1, MacNamara, C.1, Uhl, L.1, Avivi, I.3, Katz, T.3,
Zarwan, C.1, Joyce, R.1, Levine, J.D.1, Lowe, K.1, Dombagoda, D.1,
Tzachanis, D.1, Boussiotis, V.1, Giallombardo, N.1, Mortellite, J.1,
Conway, K.1, Fitzgerald, D.1, Richardson, P.2, Anderson, K.2,
Munshi, N.2, Rowe, J.3, Tsumer, M.3, Bishart, L.3, Kufe, D.2 1 Beth Israel
Deaconess Medical Center, Boston, MA; 2 Dana Farber Cancer Institute,
Boston, MA; 3 Rambam Medical Center, Haifa, Israel
Autologous transplantation results in improved outcomes in pa-
tients with multiple myeloma (MM), but patients relapse from
persistent disease. A promising area of investigation is the develop-
ment of cancer vaccines that educate host immunity to target mye-
loma cells. We have developed a cancer vaccine in which DCs are
fused to autologous MM cells. We are conducting a study in which
patients with MM undergo stem cell transplantation followed by
post-transplant vaccination with DC/MM fusions. DCs were gener-
ated from adherent mononuclear cells cultured with GM-CSF and
IL-4 and TNFa. Myeloma cells were isolated from bone marrow as-
pirates. DC and MM cells were fused with polyethylene glycol. To
date, 26 patients have been enrolled. Mean yield of the DC and my-
eloma preparations was 171  106 and 70  106 cells, respectively.
Mean fusion efficiency was 40% and the mean cell dose generated
was 4 106 fusion cells. As ameasure of their potency as antigen pre-
senting cells, fusion cells potently stimulated allogeneic T cell pro-
liferation in vitro. Mean stimulation indexes were 12, 57, 31 for T
cells stimulated by MM cells, DCs, and fusions. Adverse events
were mild. 14 patients have completed vaccinations of which 8have achieved a complete remission and 6 a partial remission. Of
note, 4 patients achieved complete remission only with vaccination.
T cell responses to PHA and tetanus toxoid were depressed post-
transplant. In contrast, a significant increase was noted post-trans-
plant in circulating tumor reactive lymphocytes as determined by
T cell expression of IFNg following ex vivo exposure to autologous
myeloma cell lysate (Mean percentage of tumor reactive CD8 cells
was 0.9 and 11 pre and post-transplant, respectively p 5 0.01;
mean percentage of CD4 cells was 0.7 and 2.7; p 5 0.02). A further
amplification of tumor reactive lymphocytes was seen with vaccina-
tion (mean percentage of CD4 and CD8 tumor reactive T cells was
4.9 and 15, respectively). A decrease in circulating regulatory T cells
was observed following transplantation. In summary, fusion cell
vaccination in conjunction with stem cell transplantation was well
tolerated, induced anti-tumor immunity and clinical responses.
The post-transplant period is characterized by decreased levels of
regulatory T cells and enhanced levels of tumor reactive T cells.
The increase in tumor reactive T cells post-transplant is further
amplified following vaccination with DC/MM fusion cells.175
PRODUCTION OF MAGE-A4-SPECIFIC CTL FROM HEALTHY DONORS,
PATIENTS, AND CORD BLOOD FOR LYMPHOMA THERAPY AFTER TRANS-
PLANT
Cruz, C.R.Y.1, Leen, A.M.1, Shafer, J.A.1, Younes, A.2, Rooney, C.M.1,
Gerdemann, U.1, Christin, A.S.1, Heslop, H.E.1, Bollard, C.M.1 1 Baylor
College of Medicine, Houston, TX; 2 MD Anderson Cancer Center,
Houston, TX
Patientswho relapsewithHodgkin’s Lymphoma (HL) – often pre-
senting with chemo- and radio- resistant disease – may benefit from
immunotherapeutic strategies as adjuvant or salvage therapy after he-
matopoietic stem cell transplantation (HSCT). We have previously
demonstrated that infusion of cytotoxic T cells directed against Ep-
stein Barr virus (EBV)-derived proteins expressed in tumors induced
complete remissions in patients with relapsed EBV-positive HL.
However, approximately 70% of relapsed lymphomas are EBV-
negative. Therefore, we investigated the use of another immunother-
apeutic target, the cancer/testis antigen MAGE-A4, which is
frequently expressed by Hodgkin Reed Sternberg cells. The re-
stricted expression of this protein in immune-privileged germ cells
andmalignant cells makes it an attractive target for the ex vivo gener-
ation of tumor-specific T cells. Using dendritic cells pulsed with an
overlapping peptide library spanning the entire MAGE A4 protein
as antigen presenting cells, and culturing responder T cells in the
presence of the cytokines IL7, IL12, and IL15, we have successfully
expandedMAGE-A4-specificT cells fromdifferent sources of hema-
topoietic stem cells: patients with Hodgkin’s Lymphoma (n 5 3),
healthy donors (n 5 5), and umbilical cord blood (n 5 1). After 2
weeks expansion, 4of 8CTL lines contained ameanof 62.62%(range
49.55 – 79.86%) CD81 and 11.41% (range 1.64 – 17.88%) CD41
T-cells. ELISPOT assays on CTL lines demonstrated a mean of
147.54 (range 29–716) IFNg-producing cells (IPC)/1 10e5T-cells
following incubation with MAGE A4 peptides. No significant re-
sponse to irrelevant peptides was demonstrated (mean 9.14; range
2–21.5 IPC/10e5 cells). Peptide pool mapping allowed us to identify
a single, previously uncharacterized epitope (aa266–285, the NPAR-
YEFLWGPRALAETSYV peptide) in the majority of healthy do-
nors. Additional analysis on an evaluable CTL line showed that the
response to the NPA peptide was mediated by CD81T cells, which
demonstrated cytotoxic activity against peptide-pulsed autologous
targets using the Cr51 release assay. These early results suggest that
adoptive immunotherapy utilizing allogeneic, autologous or umbili-
cal cord blood as sources of T cells is a promising approach for the
treatment of relapsed HL after stem cell transplant.176
BORTEZOMIB TARGETS STROMA-MEDIATED APO2L/TRAIL APOPTOSIS
RESISTANCE IN MULTIPLE MYELOMA
Perez, L.E.1, Parquet, N.1, Anasetti, C.1, Dalton, W.2 1 H Lee Moffitt
Cancer Center & Research Institute, Tampa, FL; 2 H Lee Moffitt Cancer
Center & Research Institute, Tampa, FL
APO2L/TRAIL mediates graft versus tumor (GVT) responses
while sparing normal tissues. We have shown that stroma promotes
